## Eloi Magnin

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8634839/publications.pdf

Version: 2024-02-01

346980 299063 2,134 96 22 h-index citations papers

42 g-index 106 106 106 4143 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype. Brain Sciences, 2022, 12, 183.	1.1	8
2	What (more) can verbal fluency tell us about multiple sclerosis?. Annals of Physical and Rehabilitation Medicine, 2021, 64, 101394.	1.1	6
3	Neurodevelopmental and Neurodegenerative Similarities and Interactions: A Point of View About Lifelong Neurocognitive Trajectories. Journal of Alzheimer's Disease, 2021, 79, 1397-1407.	1.2	7
4	Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers. Acta Neuropathologica, 2021, 142, 259-278.	3.9	8
5	Repetitive Transcranial Magnetic Stimulation as an Add-On Treatment for Cognitive Impairment in Alzheimer's Disease and Its Impact on Self-Rated Quality of Life and Caregiver's Burden. Brain Sciences, 2021, 11, 740.	1.1	5
6	Evaluation of Attachment Style and Social Support in Patients With Severe Migraine. Applications in Doctor-Patient Relationships and Treatment Adherence. Frontiers in Neurology, 2021, 12, 706639.	1.1	4
7	Neural Activation in Risky Decision-Making Tasks in Healthy Older Adults: A Meta-Analysis of fMRI Data. Brain Sciences, 2021, 11, 1043.	1.1	9
8	Added value of functional neuroimaging to assess decision-making capacity of older adults with neurocognitive disorders: protocol for a prospective, monocentric, single-arm study (IMAGISION). BMJ Open, 2021, 11, e053549.	0.8	1
9	Medical teachers' opinions about students with neurodevelopmental disorders and their management. BMC Medical Education, 2021, 21, 16.	1.0	3
10	Association of Amyotrophic Lateral Sclerosis and Alzheimer's Disease: New Entity or Coincidence? A Case Series. Journal of Alzheimer's Disease, 2021, 84, 1439-1446.	1.2	2
11	Cognitive Impairment in Late-Life Depression: A Comparative Study of Healthy Older People, Late-Life Depression, and Mild Alzheimer's Disease Using Multivariate Base Rates of Low Scores. Frontiers in Psychology, 2021, 12, 724731.	1.1	5
12	Characteristics of Bipolar Patients with Cognitive Impairment of Suspected Neurodegenerative Origin: A Multicenter Cohort. Journal of Personalized Medicine, 2021, 11, 1183.	1.1	5
13	Contribution of cerebrospinal fluid Alzheimer biomarkers to the diagnosis of Creutzfeldtâ€Jakob disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
14	Functional movement disorders. Revue Neurologique, 2020, 176, 244-251.	0.6	16
15	What Are the Minimal Detectable Changes in SDMT and Verbal Fluency Tests for Assessing Changes in Cognitive Performance in Persons with Multiple Sclerosis and Non-Multiple Sclerosis Controls?. European Neurology, 2020, 83, 263-270.	0.6	4
16	Semantic loss marks early Alzheimer's diseaseâ€related neurodegeneration in older adults without dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12066.	1.2	20
17	Comparison of Noninvasive Imagery Methods to Observe Healthy and Degenerated Olfactory Epithelium in Mice for the Early Diagnosis of Neurodegenerative Diseases. Frontiers in Neuroanatomy, 2020, 14, 34.	0.9	3
18	Cerebrospinal Fluid Levels of Kininogenâ€1 Indicate Early Cognitive Impairment in Parkinson's Disease. Movement Disorders, 2020, 35, 2101-2106.	2.2	16

#	Article	IF	CITATIONS
19	Phenotypes associated with MAPT duplications. Alzheimer's and Dementia, 2020, 16, e042008.	0.4	0
20	Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 74, 903-911.	1.2	9
21	IncRNAs as a novel source of diagnostic applications for early Alzheimer's disease and other dementia types. Alzheimer's and Dementia, 2020, 16, e039788.	0.4	O
22	Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer's Disease Before 51 Years. Journal of Alzheimer's Disease, 2019, 71, 227-243.	1.2	39
23	Diagnosis associated with Tau higher than 1200†pg/mL: Insights from the clinical and laboratory practice. Clinica Chimica Acta, 2019, 495, 451-456.	0.5	13
24	What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France. BMJ Open, 2019, 9, e026380.	0.8	17
25	Historical Pathway from Description of Cognitive Recovery to Formal Neuropsychological Rehabilitation. Frontiers of Neurology and Neuroscience, 2019, 44, 179-191.	3.0	O
26	Modification of both functional neurological symptoms and neuroimaging patterns with a good anatomoclinical concordance: a case report. BMC Neurology, 2019, 19, 270.	0.8	3
27	Unstable TTTTA/TTTCA expansions in MARCH6 are associated with Familial Adult Myoclonic Epilepsy type 3. Nature Communications, 2019, 10, 4919.	5.8	111
28	Evidence for a neural signature of musical preference during silence. International Journal of Psychophysiology, 2018, 125, 50-56.	0.5	5
29	Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 467-475.	0.9	30
30	The RAPID-II Neuropsychological Test battery for subjects aged 20 to 49 years: Norms and cognitive profile. Revue Neurologique, 2018, 174, 44-55.	0.6	4
31	Saccadic Eye Movements and Attentional Control in Alzheimer's Disease. Archives of Clinical Neuropsychology, 2018, 33, 1-13.	0.3	39
32	Pali and Echo Phenomena: Symptoms of Persistence and Perseveration. Frontiers of Neurology and Neuroscience, 2018, 41, 28-39.	3.0	2
33	Added value of <sup>18</sup> Fâ€florbetaben amyloid PET in the diagnostic workup of most complex patients with dementia in France: A naturalistic study. Alzheimer's and Dementia, 2018, 14, 293-305.	0.4	48
34	Prevalence of amyloidâ $\in$ $\hat{i}^2$ pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
35	ADDIA, A MULTICENTER CLINICAL STUDY OF PROOF-OF-PERFORMANCE TO VALIDATE BLOOD-BASED BIOMARKERS FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD): THE STUDY PROTOCOL. , 2018, 14, P781.		O
36	Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers. Current Alzheimer Research, 2018, 15, 691-700.	0.7	5

#	Article	IF	Citations
37	Improvement of Response to Cueing after Left Prefrontal Transcranial Direct Current Stimulation in Alzheimers disease. Neuropsychiatry, 2018, 08, .	0.4	2
38	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.4	423
39	GREFON recommendations for assessment of instrumental activities of daily living in memory clinics. Revue Neurologique, 2017, 173, 194-200.	0.6	2
40	Multiple Sclerosis and Clinical Gait Analysis before and after Fampridine: A Systematic Review. European Neurology, 2017, 78, 272-286.	0.6	17
41	Attention-deficit/hyperactivity disorder during adulthood. Revue Neurologique, 2017, 173, 506-515.	0.6	40
42	Contribution to Alzheimer's disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls. Neurobiology of Aging, 2017, 59, 220.e1-220.e9.	1.5	116
43	Effects of a Training Program Involving Body Cooling on Physical and Cognitive Capacities and Quality of Life in Multiple Sclerosis Patients: A Pilot Study. European Neurology, 2017, 78, 71-77.	0.6	17
44	Long-term cognitive outcome of Alzheimer's disease and dementia with Lewy bodies: dual disease is worse. Alzheimer's Research and Therapy, 2017, 9, 47.	3.0	28
45	[P1–240]: CLINICAL IMPACT OF CEREBROSPINAL FLUID BIOMARKERS IN MILD COGNITIVE IMPAIRMENT DIAGNOSIS. Alzheimer's and Dementia, 2017, 13, P336.	0.4	1
46	Cognitive Impairment Involving Social Cognition in SPG4 Hereditary Spastic Paraplegia. Behavioural Neurology, 2016, 2016, 1-6.	1,1	13
47	Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers. Journal of Alzheimer's Disease, 2016, 54, 1459-1471.	1.2	28
48	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.4	93
49	Slowing of information processing speed without motor slowing in multiple sclerosis observed during two crossing-off tasks. Revue Neurologique, 2016, 172, 225-230.	0.6	7
50	Don't forget the lyrics! Spatiotemporal dynamics of neural mechanisms spontaneously evoked by gaps of silence in familiar and newly learned songs. Neurobiology of Learning and Memory, 2016, 132, 18-28.	1.0	7
51	Executive and Attentional Disorders, Epilepsy and Porencephalic Cyst in Autosomal Recessive Cerebellar Ataxia Type 3 Due to <b><i>ANO10</i></b> Mutation. European Neurology, 2016, 75, 186-190.	0.6	19
52	Left Prefrontal Repetitive Transcranial Magnetic Stimulation in a Logopenic Variant of Primary Progressive Aphasia: A Case Report. European Neurology, 2016, 76, 12-18.	0.6	19
53	Isolated pure verbal amnesia as the disease onset of probable multiple sclerosis with a left forniceal black hole. Revue Neurologique, 2016, 172, 396-398.	0.6	1
54	Mystery Case: <i>CSF-1R</i> mutation is a cause of intracranial cerebral calcifications, cysts, and leukoencephalopathy: [RETRACTED]. Neurology, 2016, 87, e262-e263.	1.5	12

#	Article	IF	Citations
55	Fampridine and quality of life in individuals with multiple sclerosis. SpringerPlus, 2016, 5, 1070.	1.2	11
56	Mnesic Profiles According to the Size of Pericerebral Hematoma in Patients with Traumatic Brain Injury. European Neurology, 2016, 74, 303-309.	0.6	0
57	Age, Neurological Status MRC Scale, and Postoperative Morbidity are Prognostic Factors in Patients with Glioblastoma Treated by Chemoradiotherapy. Clinical Medicine Insights: Oncology, 2016, 10, CMO.S38474.	0.6	8
58	Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study. Alzheimer's Research and Therapy, 2016, 8, 27.	3.0	18
59	SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Molecular Psychiatry, 2016, 21, 831-836.	4.1	96
60	Facial Emotion Recognition and Faux Pas Interpretation in Multiple Sclerosis. Brain Impairment, 2015, 16, 158-172.	0.5	6
61	Left Temporal Lobe Epilepsy Revealing Left Posterior Cortical Atrophy Due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 521-526.	1.2	10
62	Spectrum Effect and Spectrum Bias inÂtheÂScreening Test Performance forÂAmnestic Mild Cognitive Impairment: What are the Clinical Implications?. Journal of Alzheimer's Disease, 2015, 48, 385-393.	1.2	5
63	On the difficulty to communicate with fMRI-based protocols used to identify covert awareness. Neuroscience, 2015, 300, 448-459.	1.1	9
64	F2-03-04: Genetic risk factors for posterior cortical atrophy., 2015, 11, P168-P169.		2
65	A New Symptom, †Palinendophonia', Associated with Pure Verbal Palinacousis Induced by a Right Inferior Temporal Lesion. European Neurology, 2015, 74, 219-221.	0.6	2
66	Adult-onset genetic leukoencephalopathies: A MRI pattern-based approach in a comprehensive study of 154 patients. Brain, 2015, 138, 284-292.	3.7	58
67	Logopenic syndrome and corticobasal dysfunction in a "benign―type 3 familial cortical myoclonic tremor with epilepsy. Seizure: the Journal of the British Epilepsy Association, 2015, 25, 84-86.	0.9	3
68	Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis. European Neurology, 2015, 74, 243-250.	0.6	16
69	An fMRI study on the influence of sommeliers' expertise on the integration of flavor. Frontiers in Behavioral Neuroscience, 2014, 8, 358.	1.0	35
70	A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles. Alzheimer's Research and Therapy, 2014, 6, 38.	3.0	44
71	Late Diagnosis of COL4A1 Mutation and Problematic Vascular Risk Factor Management. European Neurology, 2014, 72, 150-152.	0.6	4
72	Neuropsychological and neuroimaging phenotype induced by a CAMTA1 mutation. Brain and Development, 2014, 36, 711-715.	0.6	7

#	Article	IF	CITATIONS
73	Impact of cerebro-spinal fluid biomarkers of Alzheimer's disease in clinical practice: a multicentric study. Journal of Neurology, 2014, 261, 144-151.	1.8	56
74	Conversion, dissociative amnesia, and Ganser syndrome in a case of "chameleon―syndrome: Anatomo-functional findings. Neurocase, 2014, 20, 27-36.	0.2	12
75	Increased Cerebrospinal Fluid Tau Levels in Logopenic Variant of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 611-616.	1.2	9
76	P1-129: CSF AD BIOMARKERS IN MEMORY CLINIC PATIENTS: THE EP.L.M.FR STUDY., 2014, 10, P347-P347.		0
77	O1-09-01: IMPACT OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE IN CLINICAL PRACTICE: A MULTICENTRIC STUDY. , 2014, 10, P146-P147.		o
78	Logopenic syndrome in posterior cortical atrophy. Journal of Neurology, 2013, 260, 528-533.	1.8	51
79	Effects of an ambient odor on brain activations during episodic retrieval of objects. Brain Imaging and Behavior, 2013, 7, 213-219.	1.1	6
80	Transient improvement in sensorimotor conversion during post-anoxic encephalopathy with bilateral medial temporal ischemia. Neurocase, 2013, 19, 576-582.	0.2	0
81	Mesencephalic cavernoma, abnormal DATâ€SPECT, and corticobasal and crossed cerebellar hypoperfusion. Movement Disorders, 2013, 28, 442-442.	2.2	1
82	Initial Neuropsychological Profile of a Series of 20 Patients with Logopenic Variant of Primary Progressive Aphasia. Journal of Alzheimer's Disease, 2013, 36, 799-808.	1.2	35
83	Amyloid-Related Imaging Abnormalities in AÎ <sup>2</sup> PP Duplication Carriers. Journal of Alzheimer's Disease, 2013, 37, 789-793.	1.2	9
84	Can Chronic Remote Cortical Hypoperfusion Induced by Thalamic Infarction Cause Damage of Tracts Passing through Those Hypoperfused Regions?. Frontiers in Neurology, 2013, 4, 156.	1.1	1
85	Update in Familial Cortical Myoclonic Tremor with Epilepsy. , 2013, , 249-262.		1
86	Intragenic <i>CAMTA1</i> rearrangements cause non-progressive congenital ataxia with or without intellectual disability. Journal of Medical Genetics, 2012, 49, 400-408.	1.5	39
87	Cerebellar White Matter T <sub>2</sub> Hyperintense Lesions in Isolated Hyperbilirubinemic Hepatic Encephalopathy. European Neurology, 2012, 68, 47-47.	0.6	1
88	A New Form of Leukoencephalopathy with Calcifications and Cysts with Nonrecessive Inheritance and Absence of Gadolinium Enhancement. European Neurology, 2012, 67, 151-153.	0.6	15
89	Fractional Anisotropy in Three Variants of Primary Progressive Aphasia. European Neurology, 2012, 68, 229-233.	0.6	11
90	Fronto-striatal dysfunction in type 3 familial cortical myoclonic tremor epilepsy occurring during aging. Journal of Neurology, 2012, 259, 2714-2719.	1.8	8

#	Article	IF	CITATIONS
91	A case report of daily left prefrontal repetitive transcranial magnetic stimulation (rTMS) as an adjunctive treatment for Alzheimer disease. Brain Stimulation, 2012, 5, 264-266.	0.7	53
92	Dominant Optic Atrophy, Neuropathy, Ataxia, White Matter FLAIR Hypersignals, Middle Cerebellar Peduncule Atrophy and Asthenia in OPA1 Mutation. European Neurology, 2012, 67, 287-287.	0.6	3
93	Classification and stratification of primary progressive aphasia: CSF biomarkers as a useful tool?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 671-671.	0.9	3
94	Bipolar disorder and dementia: where is the link?. Psychogeriatrics, 2011, 11, 60-67.	0.6	28
95	Unusual Dopaminergic Depletion in Variant Creutzfeldt-Jakob Disease with Early and Rapid Cognitive Decline. European Neurology, 2011, 65, 368-368.	0.6	6
96	Stiff Leg Syndrome and Myelitis with Anti-Amphiphysin Antibodies: A Common Physiopathology. European Neurology, 2011, 66, 253-255.	0.6	14